Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 16/20 | 0.77 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30134102 | 1.00 | PDE2A (0.77) | PDE2ALIPGGAASLC6A2SLC6A4 | |
| SCHEMBL1035450 | 0.87 | PDE2A (1.00) | PDE2AGAASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18290607 | 0.87 | PDE2A (0.59) | PDE2A | |
| SCHEMBL2272447 | 0.86 | PDE2A (0.58) | PDE2A | |
| SCHEMBL2272444 | 0.86 | PDE2A (0.58) | PDE2A | |
| SCHEMBL2272449 | 0.86 | PDE2A (0.58) | PDE2A | |
| SCHEMBL25376231 | 0.85 | PDE2A (0.57) | PDE2ALIPG | |
| SCHEMBL10107301 | 0.85 | PDE2A (0.61) | PDE2ALIPGGAASLC6A2SLC6A4 | |
| SCHEMBL84521 | 0.84 | PDE2A (0.70) | PDE2AIDO1 | |
| SCHEMBL30481795 | 0.82 | PDE2A (0.68) | PDE2ALIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113501787-A | Method for synthesizing 6-trifluoromethyl-3-methylindazole | 黑龙江省科学院石油化学研究院 | 2021-10-15 | — | — | CN | claimed |
| US-20250353858-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| US-12325702-B2 | ATF6 inhibitors and uses thereof | ALTOS LABS, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20240327417-A1 | HETEROCYCLIC COMPOUNDS | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-03 | — | — | US | disclosed |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-08-15 | — | — | US | disclosed |
| US-20240124434-A1 | ATF6 INHIBITORS AND USES THEREOF | ALTOS LABS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-116947839-A | Amino alcohol compound, oxazoline compound, preparation method and application thereof | 中国科学院福建物质结构研究所 | 2023-10-27 | — | — | CN | disclosed |
| WO-2023125681-A1 | HETEROCYCLIC COMPOUNDS | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| EP-3285581-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-3270926-A1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-01-24 | — | — | EP | disclosed |
| CN-107530343-A | Triazolylpyridine ketones compound as PDE2 inhibitor | 默沙东公司 | 2018-01-02 | — | — | CN | disclosed |
| WO-2016196417-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196417-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016192083-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016179059-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016154081-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016154081-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016149058-A1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124434-A1 | ATF6 INHIBITORS AND USES THEREOF | ATF4, XBP1, ATF1 | PDE2A 3597/4885LIPG 418/4885GAA 214/4885 |
| US-12325702-B2 | ATF6 inhibitors and uses thereof | ATF4, XBP1, ATF1 | PDE2A 3597/4885LIPG 418/4885GAA 214/4885 |
| US-20250353858-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKK, DGKA | PDE2A 1596/4885LIPG 487/4885GAA 1782/4885 |
| US-20240327417-A1 | HETEROCYCLIC COMPOUNDS | NFATC1, CD4, ACIN1 | PDE2A 2623/4885LIPG 2879/4885GAA 1734/4885 |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | PDE2A 986/4885LIPG 2983/4885GAA 3007/4885 |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | PDE2A 986/4885LIPG 2983/4885GAA 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.